Home
NewsNewsCDSCO Orders on IVF Medical Devices reinforce strict regulatory oversight across India’s fertility sector. The directive mandates licensing compliance under existing laws, ensuring IVF and ART devices meet safety and quality standards. This move aims to curb unauthorized sales, strengthen enforcement, and bring greater accountability to medical device usage in reproductive healthcare.
Through a recent notice, the Central Drugs Standard Control Organization (CDSCO) has directed strict regulatory oversight on the import, manufacture, sale, and distribution of medical devices used in In Vitro Fertilization (IVF) and Assisted Reproductive Technology (ART) procedures. This move, highlighted under CDSCO Orders on IVF Medical Devices, reinforces the need for compliance across the sector.
The directive highlights that all medical devices are regulated under the provisions of the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017, and require appropriate licensing for import, manufacturing, sale, and distribution, except for Class A non-sterile and non-measuring medical devices. Under the CDSCO Orders on IVF Medical Devices, adherence to these frameworks has been strongly reiterated.
It further clarifies that devices used in IVF procedures, including IUI (Intrauterine Insemination) kits and centrifuges for sperm washing, fall within the definition of medical devices under the existing regulatory framework. The CDSCO has taken note of instances where firms are selling medical devices intended for In Vitro Fertilization viz., IUI (Intrauterine Insemination) kits, centrifuges for sperm washing, etc., used for Assisted Reproductive Technology related procedures without obtaining a licence from the licensing authority under the Medical Devices Rules, 2017.
In response, the apex drug regulator has instructed all State and Union Territory drug control and licensing authorities to maintain strict vigilance and ensure that no such devices are imported, manufactured, distributed, or sold without compliance with the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017. This enforcement push forms a critical part of the ongoing CDSCO Orders on IVF Medical Devices.
The notice concluded by directing all State/UT Drugs Control and Licensing Authorities, Zonal, Sub-Zonal and Port Offices of the Central Drugs Standard Control Organization (CDSCO), as well as stakeholders through its official website, stating: "You are requested to keep strict vigil & ensure that no such devices used for In Vitro Fertilization for Assisted Reproductive Technology related procedures are being imported, manufactured, distributed, sold without bidance to the Drugs and Cosmetics Act,1940 and Medical Devices Rules, 2017."
The circular has been addressed to all State/UT Drugs Control and Licensing Authorities, along with all Zonal, Sub-Zonal, and Port Offices of CDSCO. It has also been shared with stakeholders via the CDSCO website for wider awareness and compliance.
Abu Dhabi University and FertiClinic Group have joined forces to establish the FertiClinic Reproductive Research Lab, an advanced reproductive research lab in Abu Dhabi housing IVF, andrology, and cryopreservation facilities. The partnership supports UAE national priorities, bridges academic and clinical expertise, and advances fertility innovation across the region.
NHS Kent and Medway has overhauled its fertility funding policy in a move that sees NHS cuts IVF access for thousands of patients. Effective 1 April 2026, the eligible age ceiling drops from 40 to 38, funded cycles fall from two to one, and embryo transfers are capped at two.
ASEAN's First Telemedicine IVF by Inspire IVF introduces a new era of remote fertility care. Combining AI technology with expert consultation, the platform enables global access, real-time monitoring, and personalised treatment planning, positioning Thailand as a leading hub for fertility services and advancing digital transformation in reproductive healthcare.
CSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
Wisconsin lawmakers from both parties are proposing bills to reduce IVF treatment costs. Republicans suggest a $5,000 tax credit for expenses, while Democrats want mandatory insurance coverage. With IVF cycles costing $20,000-$30,000 and 170,000 residents facing infertility, both parties seek affordable solutions through different approaches.
The AI-specialized Infertility Center, which is the largest in Asia, is open in Magok, Seoul and has begun its full-scale medical services from November 17 thereby marking the new era when it comes to fertility in the region.
Alife Health secured CE Mark approval for its AI-powered embryo selection tool, Embryo Predict, under EU MDR, expanding its fertility technology presence across Europe.
